TIME TRENDS IN CARDIOVASCULAR DRUG TREATMENT AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE HEART FAILURE

TIME TRENDS IN CARDIOVASCULAR DRUG TREATMENT AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE HEART FAILURE

A32.E307 JACC March 9, 2010 Volume 55, issue 10A CARDIAC FUNCTION AND HEART FAILURE TIME TRENDS IN CARDIOVASCULAR DRUG TREATMENT AND CARDIOVASCULAR E...

63KB Sizes 0 Downloads 5 Views

Recommend Documents

Plasma Corin as a Predictor of Cardiovascular Events in Patients With Chronic Heart Failure
The aim of this study was to determine the prognostic value of plasma corin in patients with chronic heart failure (CHF)

Sodium sensitivity and cardiovascular events in patients with essential hypertension
In patients with sodium-sensitive hypertension, glomerular pressure is increased and microalbuminuria, a marker of glome

Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure
Acute heart failure (AHF) is a life-threatening disease requiring urgent treatment, including a recommendation for immed

Exercise, cardiovascular disease, and chronic heart failure
Humphrey R, Bartels MN. Exercise, cardiovascular disease, and chronic heart failure. Arch Phys Med Rehabil 2001;82 Suppl

212: Death and cardiovascular events in patients with acute coronary syndrome and abdominal aortic aneurysm
Abdominal aortic aneurysm (AAA) is associated with peripheral and coronary artery disease (CAD), however little is known

Cardiovascular events in patients with systemic lupus erythematosus
Cardiovascular involvement represents the leading cause of mortality in SLE patients. Its most common manifestations inc

A32.E307 JACC March 9, 2010 Volume 55, issue 10A

CARDIAC FUNCTION AND HEART FAILURE TIME TRENDS IN CARDIOVASCULAR DRUG TREATMENT AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE HEART FAILURE ACC Poster Contributions Georgia World Congress Center, Hall B5 Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.

Session Title: Epidemiology, Medication and Advanced Directives Abstract Category: Myocardial Function/Heart Failure--Clinical Pharmacological Treatment Presentation Number: 1178-53 Authors: Olav R. De Peuter, Gregory Y. Lip, Olaf H. Klungel, Patrick C. Souverein, Deirdre Lane, Harry R. Büller, Anthonius De Boer, Pieter W. Kamphuisen, Academic Medical Center, Amsterdam, The Netherlands Background: Heart failure (HF) is associated with an increased risk of thrombotic events, which can be reduced by adequate drug treatment. We assessed the temporal relationship of the incidence of myocardial infarction (MI) and stroke, and the specific cardiovascular treatment that was given. Methods: Data were obtained from the PHARMO Record Linkage System, a population-based registry of pharmacy records linked with hospital discharge records in The Netherlands. Patients were selected based on a first hospital discharge diagnosis of documented HF. Two time intervals were compared: 1998-2002 and 2003-2007. We analyzed prescribed medication in the first 90 days after hospitalization, and the occurrence of MI and strokes in the first year after hospitalization. Logistic-regression analysis was performed to calculate odds ratios (OR) between the two periods. Results: We identified 6526 patients in 1998-2002 and 6369 patients from 2003-2007. During the first year after acute HF, the incidence of thrombotic events was 4.1% and 3.4% in the two periods, respectively. After adjustment for age and previous thrombotic events the incidence was 21% lower in 2003-2007 (Table). Prescription of ACE-inhibitors and beta-blockers has increased in the recent years, but were still prescribed to only 60% of HF patients (Table). Conclusion: The incidence of thrombotic events appears to have decreased in patients with acute HF, which may be due to better use of medication. However, many patients remain undertreated. Differences between the time-periods 1998-2002 and 2003-2007 in thrombotic events and medication 1998-2002 2003-2007 (n=6526) (n=6369) Overall atherothrombotic events 265 (4.1) 214 (3.4) Myocardial infarction 204 (3.1) 160 (2.5) Ischemic stroke 63 (1.0) 55 (0.9) ACE inhibitor or ARB 3760 (58) 4010 (63) Beta-blockers 2552 (39) 3806 (60) Coumarins 2051 (31) 2328 (37) Antiplatelets 1962 (30) 2196 (34) Statins 1165 (18) 2065 (32)

OR (95%CI) 0.79 (0.66 -0.95)† 0.76 (0.62 -0.94)† 0.88 (0.61 -1.26)† 1.25 (1.17-1.34) 2.31 (2.16-2.48) 1.26 (1.17-1.35) 1.22 (1.14-1.32) 2.21 (2.03-2.40)

Footnote: ARB=Angiotensin Receptor Blocker. OR=Odds Ratio. †Adjusted for age and previous cardiovascular events.